Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAGER: MiyaBM (butyric acid preparation) in unresectable hepatocellular carcinoma on durvalumab + tremelimumab
jRCTs061230077Recruiting
- Start
- Apr 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of MO-03 in hepatocellular carcinoma (HCC). Primary endpoint: Progression-free survival. Started Apr 2024; status: recruiting.
02
Drugs
MO-03
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs061230077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061230077.